ABSTRACT
Background COVID-19 infection in pregnancy is associated with a higher risk of progression to severe disease, but vaccine uptake by pregnant women is hindered by persistent safety concerns. COVID-19 vaccination in pregnancy has been shown to reduce stillbirth, but its relationship with preterm birth is uncertain.
Objective The aim of this study was to investigate the sociodemographic characteristics associated with vaccine uptake in Melbourne, Australia, and to compare perinatal outcomes by vaccination status.
Study design Retrospective multicenter cohort study in Melbourne following the national recommendations for mRNA COVID-19 vaccination during pregnancy in June 2021. Routinely collected data from all 12 public maternity hospitals in Melbourne were extracted on births ≥ 20 weeks’ gestation from 1st July 2021 to 31 March 2022. Maternal sociodemographic characteristics were analyzed from the total birth cohort. Perinatal outcomes were compared between vaccinated and unvaccinated women for whom weeks 20-43 of gestation fell entirely within the 9-month data collection period. The primary outcome was the rate of congenital anomaly in singleton infants ≥ 20 weeks’ gestation among women vaccinated during pregnancy. Secondary perinatal outcomes including stillbirth, preterm birth (spontaneous and iatrogenic), birthweight ≤ 3rd centile, and newborn intensive care unit admissions were examined for singleton infants ≥ 24 weeks’ gestation without congenital anomalies. We calculated the adjusted odds ratio of congenital anomalies and perinatal outcomes among vaccinated versus unvaccinated women using inverse propensity score weighting regression adjustment with multiple covariates; p< 0.05 was considered statistically significant.
Results Births from 32,536 women were analyzed: 17,365 (53.4%) were vaccinated and 15,171 (47.6%) were unvaccinated. Vaccinated women were significantly more likely to be older, nulliparous, non-smoking, not requiring an interpreter, of higher socioeconomic status, and vaccinated against pertussis and influenza. Vaccination status also varied by region of birth: compared with women born in Australia, women born in South and Eastern Europe, the Middle East, Africa and Oceania had lower adjusted odds of vaccination. There was no significant increase in the rate of congenital anomalies or birth weight ≤ 3rd centile in vaccinated women. Vaccinated women were significantly less like to have an infant with a major congenital anomaly compared with the unvaccinated group (2.4% vs 3.0%, aOR 0.72, 95%CI 0.56-0.94, p=0.02). This finding remained significant even when the analysis was restricted to women vaccinated before 20 weeks’ gestation. Vaccinated women had a significantly lower rate of stillbirth (0.2% vs 0.8%, aOR 0.18, 95%CI 0.09-0.37, P < 0.001. Vaccination was associated with a significant reduction in total preterm births < 37 weeks (5.1% vs 9.2%, aOR 0.60, 95% CI 0.51-0.71, p< 0.001), spontaneous preterm birth (2.4% vs 4.0%, aOR 0.73 95% CI 0.56-0.96, p=0.02) and iatrogenic preterm birth (2.7% vs 5.2%, aOR 0.52, 95%CI 0.41-0.65, p< 0.001).
Conclusions COVID-19 Vaccine coverage was significantly influenced by known social determinants of health, which is likely to influence the strong association between COVID-19 vaccination and lower risks of stillbirth and preterm birth. We did not observe any adverse impacts of vaccination on fetal growth or development.
Why was this study conducted?
⍰ COVID-19 infection in pregnancy is associated with a higher risk of progression to severe disease, but vaccine uptake by pregnant women is hindered by persistent safety concerns. COVID-19 vaccination in pregnancy has been shown to reduce stillbirth, but its relationship with preterm birth is uncertain.
⍰ Most of the published literature on COVID-19 vaccination in pregnancy have methodological limitations including fixed cohort bias and time-varying exposure.
⍰ We conducted this multicenter study to provide robust evidence on mRNA COVID-19 vaccination and perinatal outcomes including congenital anomalies, stillbirth, and preterm birth.
What are the key findings?
⍰ The adjusted odds of stillbirth, preterm birth, and neonatal intensive care admission were significantly reduced among infants born to COVID-19 vaccinated women compared with unvaccinated women. COVID-19 vaccination during pregnancy was not associated with an increase in congenital anomalies.
⍰ Our results conclusively demonstrate a significant reduction in both spontaneous and iatrogenic preterm birth for vaccinated women
⍰ Vaccinated women were significantly more likely to be older, nulliparous, non-smoking, not requiring an interpreter, residing in a higher socioeconomic postcode, and vaccinated against pertussis and influenza. There were also significant differences in vaccination rates by region of birth.
What does this study add to what is already known?
⍰ Our analysis confirmed a strong relationship between the COVID-19 mRNA vaccine and lower preterm births and stillbirths
⍰ In addition to its impact on reducing severe COVID-19 illness, vaccination may be a proxy for other biological and social determinants of health among our pregnant population.
Competing Interest Statement
LH has received research funding from Ferring Pharmaceuticals outside the scope of this work. BWM is a consultant for Guerbet and has received research grants from Guerbet and Merck. KRP has received consultancy fees from Janssen. DLR has received fees from Alexion for participation in advisory boards unrelated to this work. All other authors declare no competing interests.
Funding Statement
This study was funded by the Norman Beischer Medical Research Foundation and the University of Melbourne Department of Obstetrics and Gynaecology. LH, BWM and KRP are supported by National Health and Medical Research Council investigator grants (GNT1196010, GNT11766437 and GNT2009765). The funding bodies had no role in any aspects of the design or conduct of this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was given ethical approval from the Human Research Ethics Committees of Austin Health (Ref. HREC/64722/Austin-2020) and Mercy Health (Ref. 2020-031).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
DISCLOSURES LH has received research funding from Ferring Pharmaceuticals outside the scope of this work. BWM is a consultant for Guerbet and has received research grants from Guerbet and Merck. KRP has received consultancy fees from Janssen. DLR has received fees from Alexion for participation in advisory boards unrelated to this work. All other authors declare no competing interests.
FUNDING This study was funded by the Norman Beischer Medical Research Foundation and the University of Melbourne Department of Obstetrics and Gynaecology. LH, BWM and KRP are supported by National Health and Medical Research Council investigator grants (GNT1196010, GNT11766437 and GNT2009765). The funding bodies had no role in any aspects of the design or conduct of this study.
PAPER PRESENTATION The findings of this study were submitted as a free communication for the Annual Scientific Meeting of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists at the Gold Coast, QLD, Australia in October 2022.
CONDENSATION Stillbirths, spontaneous and iatrogenic preterm births significantly lower in COVID-19 vaccinated women
Data Availability
Non-identifiable individual participant data is available on request to the Austin Health Human Research Ethics Committee (ethics{at}austin.org.au) and the Mercy Health Human Research Ethics Committee (ethics{at}mercy.com.au). The study investigators may contribute aggregate and non-identifiable individual patient data to national and international collaborations whose proposed use of the data has been ethically reviewed and approved by an independent committee and following signing of an appropriate research collaboration agreement with the University of Melbourne.
